Cagrilintide
Research profile · How we handle evidence
Cagrilintide is a long-acting amylin analog being developed by Novo Nordisk alongside semaglutide as a combination therapy known as "CagriSema". Amylin is a natural hormone involved in post-meal signaling; it helps promote fullness and reduce appetite. When paired with GLP-1 therapy, the two mechanisms are designed to reinforce appetite control and support weight management.
Evidence Score
High confidence
Category
Therapeutic area
Standard Dose
Once weekly
Half-life
Plasma elimination
Route
Subcutaneous
Safety Tier
Well characterized
Overview
Cagrilintide works like amylin, a hormone your body releases after eating to help you feel satisfied. In "CagriSema," it’s paired with semaglutide (a GLP-1 drug) to target appetite in two coordinated ways: GLP-1 signaling helps slow stomach emptying and affects hunger, while amylin signaling supports satiety. The regimen is designed for once-weekly injection and is intended for people who want stronger weight-loss support than GLP-1 therapy alone. Because this is still investigational, participants should follow the specific trial protocol and clinicians should review risks and suitability.
Mechanism of Action
Cagrilintide works like amylin, a hormone your body releases after eating to help you feel satisfied. In "CagriSema," it’s paired with semaglutide (a GLP-1 drug) to target appetite in two coordinated ways: GLP-1 signaling helps slow stomach emptying and affects hunger, while amylin signaling supports satiety. The regimen is designed for once-weekly injection and is intended for people who want stronger weight-loss support than GLP-1 therapy alone. Because this is still investigational, participants should follow the specific trial protocol and clinicians should review risks and suitability.
pH & Mixing
Peptides reconstituted at very different pH levels can destabilize when combined in the same syringe, which lowers how much of the peptide your body actually absorbs. If you're unsure whether two peptides are close enough in pH, reconstitute and inject them separately.
A dedicated compatibility check between two specific peptides is coming to the Compare tool. This section covers this peptide's pH only.
Benefits
- Enhanced satiety (feeling full)
- Targets the amylin pathway (satiety signaling)
- Designed to complement GLP-1 therapy
- Potential for improved weight-management outcomes vs single-agent therapy (investigational)
Side Effects
- Nausea (common)
- Vomiting
- Diarrhea or other GI upset
- Constipation
- Injection-site reactions
- Potential dehydration from persistent GI symptoms (seek medical advice if severe)
Contraindications
- Pregnant or breastfeeding women (insufficient safety data; avoid unless specifically approved by a clinician/trial)
- Individuals under 18 years old
- Those with known allergies to peptide components
Structure & Sequence
Verified structure
Cagrilintide
Sequence illustration backed by PubChem match.
- Amino Acid Sequence
- 39-residue acylated amylin analog (pramlintide/rat-amylin backbone with 14E/17R and 25P/28P/29P substitutions, Cys2-Cys7 disulfide bridge, C-terminal Pro-amide); N-terminally linked via a spacer to a C20 fatty diacid for albumin binding and extended half-life
- Cyclization
- Disulfide-bridged
- Molecular Weight
- 4,409 Da
- Chemical Formula
- C194H312N54O59S2
- CAS Number
- 1415456-99-3
- Reconstituted pH
- 3.5-4.5
- InChIKey
- LDERDVMBIYGIOI-IZVMHKDJSA-N
Stack & Route Context
Stacks with
- Semaglutide
Administration
Subcutaneous
Research Status
In Phase 3 clinical trials with semaglutide (CagriSema).
Approval Status
Phase3
Sports Legal
Permitted
References
- 1
CagriSema (cagrilintide + semaglutide) in obesity — clinical trial publications/updates (Phase 3)
2023
- 2
Review: Amylin analogs and incretin-based combination strategies for weight management
2022
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.